Purple Biotech (PPBT), a clinical-stage biotechnology company focused on novel cancer immunotherapies, announced a major advancement in its antibody development program with the successful manufacturing of IM1240<\/strong>, its first tri-specific antibody<\/strong> from the company\u2019s CAPTN-3 platform<\/strong>. The achievement marks the establishment of a commercially viable yield and purity level\u2014an important step toward future clinical applications.<\/p>\n\n\n\n IM1240 is designed to target 5T4<\/strong>, a tumor-associated antigen, while simultaneously engaging the CD3<\/strong> receptor on T cells and blocking the NKG2A<\/strong> inhibitory receptor on NK and CD8\u207a T cells. This triple mechanism of action<\/strong> aims to trigger a strong and localized immune response against cancer cells while reducing the risk of systemic immune activation. An Investigational New Drug (IND) submission<\/strong> is planned for 2026<\/strong>, paving the way for first-in-human trials.<\/p>\n\n\n\n CEO Gil Efron<\/strong> emphasized that developing a scalable and efficient process for producing tri-specific antibodies represents a major scientific and operational milestone. \u201cOur CAPTN-3 platform now demonstrates competitive yield and purity, positioning Purple Biotech at the forefront of next-generation immune oncology solutions,\u201d he stated.<\/p>\n\n\n\n Dr. Michael Schickler<\/strong>, Head of Clinical and Regulatory Affairs, highlighted the technical breakthrough, noting that the IM1240 antibody\u2019s protease-cleavable albumin-bound cap<\/strong> prevents systemic immune activation, focusing the immune response within the tumor microenvironment<\/strong>. This design is intended to enhance both safety and therapeutic durability.<\/p>\n\n\n\n The CAPTN-3 platform\u2019s ability to conditionally activate<\/strong> immune responses through tri-specific targeting positions Purple Biotech as an emerging leader in tumor-immune evasion<\/strong> research, combining innovation, scalability, and clinical readiness as it moves closer to first-in-human evaluation.<\/p>\n\n\n\n